| Old Articles: <Older 29171-29180 Newer> |
|---|
 |
The Motley Fool
March 18, 2008
David Lee Smith |
Builders May Lose a Vegas Bet A group of big builders faces project defaults in Las Vegas.   |
The Motley Fool
March 18, 2008
Brian Lawler |
QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker. |
The Motley Fool
March 18, 2008
Rick Aristotle Munarriz |
This Fool Doesn't Believe Yahoo! Yahoo! provides guidance, but it may be making promises its fundamentals can't keep. |
The Motley Fool
March 18, 2008
Morgan Housel |
Sex, Money, and Power In investing, just as in politics, from time to time personal actions of CEOs are held up to public judgment. |
The Motley Fool
March 18, 2008
Rich Duprey |
A Bear Market for 401(k) Plans The implosion of investment house Bear Stearns highlights the risk of investing in company stock. |
The Motley Fool
March 18, 2008
Morgan Housel |
Shuffle Master's Bad Hand Higher costs and a crumbling dollar take an ugly toll on the card shuffler maker. |
The Motley Fool
March 18, 2008
David Lee Smith |
A Steal of a Steel Deal? Two Russian companies, Evraz Group SA, and OAO TMK, are adding to their American steel holdings. |
The Motley Fool
March 18, 2008
Brian Orelli |
Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note. |
The Motley Fool
March 18, 2008
Brian Orelli |
The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will? |
The Motley Fool
March 18, 2008
Sham Gad |
Use Your Imagination and Make Money To choose the best stocks, imagine there's no market. Read on to see what we mean. |
| <Older 29171-29180 Newer> Return to current articles. |
